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Abstract
Background: Hepatocellular carcinoma (HCC) is the leading cause of primary liver cancers. Surveillance of
individuals at specific risk of developing HCC, early diagnostic markers, and new therapeutic approaches are
essential to obtain a reduction in disease-related mortality. Apurinic/apyrimidinic endonuclease 1 (APE1) expression
levels and its cytoplasmic localization have been reported to correlate with a lower degree of differentiation and
shorter survival rate. The aim of this study is to fully investigate, for the first time, the role of the mitochondrial form
of APE1 in HCC.
Methods: As a study model, we analyzed samples from a cohort of patients diagnosed with HCC who underwent
surgical resection. Mitochondrial APE1 content, expression levels of the mitochondrial import protein Mia40, and
mtDNA damage of tumor tissue and distal non-tumor liver of each patient were analyzed. In parallel, we generated
a stable HeLa clone for inducible silencing of endogenous APE1 and re-expression of the recombinant shRNA
resistant mitochondrially targeted APE1 form (MTS-APE1). We evaluated mtDNA damage, cell growth, and
mitochondrial respiration.
Results: APE1’s cytoplasmic positivity in Grades 1 and 2 HCC patients showed a significantly higher expression of
mitochondrial APE1, which accounted for lower levels of mtDNA damage observed in the tumor tissue with
respect to the distal area. In the contrast, the cytoplasmic positivity in Grade 3 was not associated with APE1’s
mitochondrial accumulation even when accounting for the higher number of mtDNA lesions measured. Loss of
APE1 expression negatively affected mitochondrial respiration, cell viability, and proliferation as well as levels of
mtDNA damage. Remarkably, the phenotype was efficiently rescued in MTS-APE1 clone, where APE1 is present only
within the mitochondrial matrix.
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Conclusions: Our study confirms the prominent role of the mitochondrial form of APE1 in the early stages of HCC
development and the relevance of the non-nuclear fraction of APE1 in the disease progression. We have also
confirmed overexpression of Mia40 and the role of the MIA pathway in the APE1 import process. Based on our
data, inhibition of the APE1 transport by blocking the MIA pathway could represent a new therapeutic approach for
reducing mitochondrial metabolism by preventing the efficient repair of mtDNA.
Keywords: Hepatocellular carcinoma, APE1, MIA pathway, Mitochondria, mtDNA damage, Base excision repair
pathway
Background
Hepatocellular carcinoma (HCC) represents between 75
and 85% of primary liver cancers [1]. It is the sixth most
prevalent malignancy and the fourth leading cause of
cancer-related deaths around the world, with about 841,
000 new cases and 782,000 deaths annually [1].
In patients with end-stage liver disease and early stage
HCC (defined by the Milan criteria according to the
EASL guidelines), liver transplantation is considered to
be the treatment option with the highest curative effect
[2]. However, limitations of liver transplantation apart
from donor shortage include the risk of dropout while
waiting (4% per month) and the perioperative mortality
rate [3]. Liver resection represents an alternative cure,
although it is only feasible in fewer than 20% of patients
because of local spread and severity of pre-existing cir-
rhosis [4]. If HCC is unresectable due to multinodular
presence or extrahepatic spread, local treatments such as
radiofrequency ablation, percutaneous ethanol injection,
and systemic therapies are the only options [4]. Surveil-
lance of individuals at specific risk of developing HCC,
early diagnostic markers, and new therapeutic targets
are essential to obtain a reduction in disease-related
mortality.
Mitochondria are essential organelles with numerous
functions in cellular metabolism and homeostasis,
among which is the energy conversion to ATP [5]. Al-
though the majority of the mitochondrial proteome is
composed of nuclear encoded proteins, each mitochon-
drion possesses multiple copies of mitochondrial DNA
(mtDNA) containing 37 genes, all of which are essential
for normal mitochondrial function [5]. Because of its
proximity to the electron transport chain (ETC), mtDNA
is subject to damage more than nuclear DNA (nDNA).
Indeed, the major source of endogenous reactive oxygen
species (ROS) is the electrons that have escaped from
the ETC [6–8]. The most extensively studied and most
common lesion caused by exposure to ROS is 8-
oxoguanine (8-oxoG). 8-oxoG has been found to be a
mutagenic lesion: mispairing of 8-oxoG with adenine re-
sults in a G-C to A-T transversion mutation during the
subsequent round of replication. This particular muta-
tion is present in significantly higher levels in mtDNA
[9, 10]; moreover, the damage has been described as
more extensive, persistent, and longer lasting than nu-
clear DNA damage in human cells following oxidative
stress [11]. To cope with damage formatting and to
maintain their functionality, mitochondria are equipped
with efficient mechanisms aimed at repairing occurring
lesions. One of the main pathways present in this organ-
elle is the mitochondrial BER pathway (mtBER), which is
involved in repairing non-helix-distorting base lesions
and contributing to maintenance of DNA stability [12].
The presence of several components of this pathway has
been documented in mitochondria, such as OGG1,
UDG, MUTY and NTH [13–17] as well as DNA ligase
III [18, 19] and APE1 [20, 21].
APE1’s localization is eminently nuclear, although this
protein is also present within the mitochondrial matrix.
APE1 is a key element of the BER pathway, both in the
nucleus and mitochondria, and aside from its endo-
nuclease activity, the protein is also a redox factor asso-
ciated with the transcriptional regulation of gene
expression [22]. Information about APE1’s subcellular
trafficking is still scanty and incomplete. What is known
is that the protein presents a bipartite nuclear
localization signal (NLS) within its N-terminal domain
that directs the protein within the nucleus [23]. Con-
cerning the mitochondrial translocation, it has been
demonstrated that APE1 uses the TOM pore complex to
pass the outer membrane [24] and reach the mitochon-
drial inner membrane space (IMS), where it becomes
the substrate of the MIA pathway [25]. However, the
mechanics explaining how the protein is further moved
into the matrix, and the molecular events conveying the
protein into the nucleus rather than mitochondria, are
still unknown.
Due to its involvement in essential cellular processes
such as genome stability and gene expression regulation,
the importance of APE1 in human pathologies such as
cancers, neurological diseases, and age-associated disor-
ders is not surprising. Many studies have shown that
APE1 is overexpressed in a variety of cancers, suggesting
a possible prognostic significance and therapeutic target
for this protein [26–29]. Data from different laboratories
support a correlation between the increased expression
Bazzani et al. BMC Cancer          (2020) 20:969 Page 2 of 13
levels of APE1 and HCC progression [30–33] and up-
hold the hypothesis that APE1 loss of expression sup-
presses proliferation and migration [34–36]. This
delineates APE1 as both a molecular marker and a drug-
gable target in HCC. However, apart from its overex-
pression, an uncanonical cytoplasmic positivity of APE1
in HCC has been reported to correlate with a lower de-
gree of differentiation and shorter survival rate [37, 38].
The aim of this study is to fully investigate, for the first
time, the role of the mitochondrial form of APE1 in
HCC.
Methods
Samples of human tumor tissue specimens and adjacent
non-tumor tissues
Samples of paired HCC and adjacent non-tumor liver tis-
sues from patients undergoing HCC resection were ob-
tained from the Department of Medicine, General Surgery
and Transplantation of the University of Udine, Udine,
Italy (Table 1). None of the patients had received any local
or systemic anticancer treatments before the surgery.
Diagnosis of HCC was performed in all cases by preopera-
tive imaging (CT or MRI scan) or by liver biopsy when re-
quested. Hepatic serology, α-fetoprotein (AFP), routine
laboratory assessment of liver and renal function were also
performed. The presence of suspected (based on radio-
logic features) neoplastic main branch portal thrombosis
was considered a contraindication to surgery [39].
After hospital discharge all patients were followed up
and monitored for tumor recurrence by monthly assess-
ments of serum AFP and by US, CT or MRI scan every
3–6 months. HCC recurrence was in all cases diagnosed
by CT or MRI imaging according to international guide-
lines [2]. This study was approved by the Unique Re-
gional Ethic Committee, August 24, 2019, Protocol
number 18659, and informed consent was obtained from
each patient.
Immunohistochemical analysis
In the registry of the Pathology Department of University
Hospital of Udine, Udine, Italy, a total of 20 patients who
had a pathological diagnosis of hepatocellular carcinoma
between January 2015 and December 2017, were identi-
fied. For each case, a single pathologist looked at slides
stained with hematoxylin-eosin to evaluate the histological
grading of HCC according to the Edmondson and Steiner
criteria. Another slide (not stained) was used for immuno-
histochemical analysis. Each slide included both the tumor
and not neoplastic liver (cirrhosis or normal liver).
Immunoistochemical detection of APE1 was per-
formed by immunohistochemistry using the anti-APE1
mouse monoclonal antibody as the primary antibody
(Novus Biologicals, Cambridge, England). The slides
were deparaffinized and rehydrated (Xylene: three
washes for 5 min each; 100% Ethanol: two washes 10
min each; 95% Ethanol: two washes 10 min each; 70%
Ethanol: two washes 10 min each; 50% Ethanol: two
washes 10 min each; distilled water: two washes for 5
min). Using microwave, the tissue sections were brought
to boil in 10 mM sodium citrate buffer (pH 6.0) and then
maintained at a sub-boiling temperature for 10 min. The
tissue sections were quenched with 3.0% hydrogen per-
oxide in methanol for at least 15 min to block endogen-
ous peroxidase activity. To permeabilize the cells, the
tissue sections were washed with 1% animal serum in
PBS with 0.4% Triton X-100 (PBS-T). Then, the tissue
sections were incubated with 5% animal serum in PBS-T
for 30 min at room temperature to block any non-
specific binding. The primary antibody (diluted 1:200;
Novus Biologicals, Cambridge, England) was added and
the tissue sections were incubated for 12 h at room
temperature and then at 4 °C overnight. A DAKO REAL
EnVision Rabbit/Mouse (K5007) was used as a second
antibody. Horseradish peroxidase activity was detected
using DAKO REAL 3,3′-diaminobenzidine + chromogen
(K5007) as substrate for 3 min in accordance with the
manufacturer’s instructions. Sections were counter-
stained with hematoxylin with a cover slip. We consider
the reaction for APE1 positive when a dense, homoge-
neous brown staining is identified in the nucleus of hep-
atocyte and when a granular brown staining is identified
in the cytoplasm of hepatocyte.
Cell culture
Stable HeLa clones for inducible silencing of endogen-
ous APE1 and re-expression of recombinant shRNA re-
sistant APE1 WT and mitochondrially targeted APE1
(MTS-APE1) were obtained as previously described [40,
41]. MTS-APE1 resistant sequence was designed substi-
tuting the N-terminal sequence involved in the nuclear
localization of the protein with the well-characterized
MTS sequence of manganese-superoxide dismutase
(MLSRAVCGTSRQLAPALGYLGSRQ) [23, 24]. Expres-
sion and localization of the recombinant protein were
confirmed by WB (Fig. 2a). APE1 silencing was induced
by addition of doxycycline to the cell culture medium at
a final concentration of 1 μg/mL for 10 days.
Nuclei and mitochondria isolation from human HCC tissue
specimens
After collection, all procedures were carried out at 4 °C
and in the presence of protease inhibitors to avoid pro-
teins degradation. Fresh samples were finely minced,
suspended in 5 mL of Isolation Buffer (IB) [10 mM Tris/
MOPS, 1 mM EGTA/Tris, 200mM Sucrose], and ho-
mogenized. Then, sample were centrifuged at 70 x g for
3 min to remove non-homogenized tissue. Supernatant
was further centrifuged at 600 x g for 10min to separate
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nuclear (pellet) and mitochondrial (supernatant) fractions.
Nuclei were washed in T1 solution [10mM HEPES pH
7.9, 0.1 mM EDTA pH 8.0, 10mM KCl, 0.1 mM MgCl2]
and then lysed in T2 solution [10mM HEPES pH 7.9, 0.1
mM EDTA pH 8.0, 400mM NaCl, 1.5 mM MgCl2, 5% gly-
cerol] for 20min on ice. After centrifugation at 14.000 x g
for 20min, the supernatant, accounting for nuclear pro-
tein extract, was collected. Mitochondria were centrifuged
at 7.000 x g for 10min, washed once in IB buffer, and then
resuspended in IB buffer. Nuclear and mitochondria pro-
tein extracts were then quantified using Bio-Rad protein
assay reagent (Bio-Rad).
mtDNA damage measurement by quantitative PCR in
patients’ samples
mtDNA isolation and damage measurement were per-
formed as previously described by Barchiesi et al. [42].
Briefly, mtDNA was extracted by patients isolated mito-
chondria from non-tumor or HCC sample using a plas-
mid isolation kit [43] and quantified by Quant-iT™
PicoGreen™ dsDNA Reagent (Invitrogen). Q-PCR was
performed on each sample to amplify a 16 ∼Kbp frag-
ment, using the following primers: FOR 5′-TCT AAG
CCT CCT TAT TCG AGC CGA-3′ and REV 5′- CCA
TCC AAC ATC TCC GCA TGA TGA AA-3′. Fluores-
cence readings of the Q-PCR reactions were quantified
in triplicate with Quant-iT™ PicoGreen™ dsDNA Reagent
(Invitrogen) and then averaged for each sample. Blank
value was subtracted and the ratio of the fluorescence
readings obtained for the tumor tissue to those of the
distal section determined the relative amplification of
the mtDNA for each patient sample. Relative mtDNA
damage was then expressed as the inverse of this relative
amplification.
Preparation of total cell extracts and subcellular
fractionation
To prepare total protein extracts, cells were harvested by
trypsinization and centrifuged at 250 x g for 5 min at
4 °C. The pellet was washed once with cold PBS and
then resuspended in Lysis buffer [50 mM Tris-HCl pH
7.5, 150 mM NaCl, 1 mM ethylenediaminetetracetic acid
(EDTA), 1% (vol/vol) Triton X-100, protease inhibitor
cocktail (Sigma), 0.5 mM phenylmethylsulfonyl fluoride
(PMSF)] at a cell density of 107 cells/mL, incubated on
ice for 30 min, and centrifuged at 20.000 x g for 20 min
at 4 °C. The supernatant was collected as total cell lysate
(TCE). For subcellular fractionation, cells were scraped
in PBS, collected, and centrifuged at 250 x g for 5 min.
Then, the pellet was suspended at a cell density of 100
mg/mL in Mitochondrial Isolation Buffer (MIB) [20 mM
HEPES pH 7.6, 1 mM EDTA, 220 mM Mannitol, 70 mM
Sucrose] supplemented with 2 mg/mL Bovine Serum Al-
bumin (BSA). Cells were mechanically broken using a 7
mL dounce homogenizer (Wheaton), centrifuged at 650
x g for 10 min at 4 °C. The pellet was conserved to pre-
pare nuclear subfraction. Supernatant collected was cen-
trifuged at 14.000 x g for 15 min at 4 °C. Isolated
mitochondria were washed with MIB supplemented with
2 mg/mL BSA and 1M KCl and centrifuged as before. A
last wash was performed using MIB without BSA, and
then mitochondria were resuspended in MIB and con-
sidered as mitochondrial protein extract (MCE). In par-
allel, nuclei were resuspended in T1 solution [10 mM
HEPES pH 7.9, 10 mM KCl, 0.1 mM MgCl2, 0.1 mM
EDTA70, 2 mM PMSF] and centrifuged at 1.000 x g for
15 min at 4 °C. This step was performed twice followed
by nuclei resuspension in T2 lysis buffer [20 mM HEPES
pH 7.9, 420 mM NaCl, 1.5 mM MgCl2, 0.1 mM EDTA70,
5% glycerol, 2 mM PMSF]. Samples were incubated on
ice for 20 min and centrifuged at 20.000 x g for 20 min
Table 1 Patients’ Demographic and Clinical Characteristics,
Tumor Features, and Outcome
Gender (M:F) 15:5
Age (years) 73 [62–77]
HBV positivity (%) 1 (5%)
HCV positivity (%) 6 (30%)
NASH (%) 3 (15%)
Alcohol abuse (%) 7 (35%)
MELD score 7 [6–10]
AFP, (ng/mL) 7.5 [3.2–23.5]
CEA, (ng/mL) 1.7 [1.1–3.3]
CA 19.9 (UI/mL) 16.9 [9.9–19.3]
Tumor number (%)
- 1 14 (70%)
- 2 4 (20%)
- 3 2 (10%)
Satellites lesions (%) 3 (15%)
Tumor max diameter (cm) 4.3 [3–10.8]
Edmonson-Steiner grading (%)
- G1 4 (20%)
- G2 12 (60%)
- G3 4 (20%)
Microvascular invasion (%) 7 (35%)
Tumor staging (%)
- T1 7 (35%)
- T2 7 (35%)
- T3 3 (15%)
- T4 3 (15%)
Tumor recurrence (%) 10 (50%)
Recurrence time, (months) 25.4 [7.4–33.5]
Continuous variables are expressed by median [interquartile range],
Categorical variables by percentage
AFP alphafetoprotein; CA 19.9 Carbohydrate Antigen 19.9, CEA
carcinoembryonic antigen, HBV hepatitis B virus, HCV hepatitis C virus, NASH
non alcoholic steatohepatitis, MELD Model for end-stage liver disease
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at 4 °C. Supernatant represented the nuclear protein
fraction (NCE).
Protein concentration was determined using Bio-Rad
protein assay reagent (Bio-Rad). Subfractions purity was
evaluated by Western blot analysis using LSD1 and
ATP5A as nuclear and mitochondria markers, respect-
ively, to exclude the presence of cross contaminations
between the two organelles.
Western blot analysis
Total (TCE), nuclear (NCE) or mitochondrial (MCE)
protein extracts were quantified via Bradford assay and
then reported amount were separated onto 12% SDS-
PAGE. Then, proteins were transferred into a nitrocellu-
lose membrane (Sartourius Stedim Biotech S.A.). Satur-
ation of the membranes was performed for 1 h at room
temperature using 5% non-fat dry milk in TBS-T
[1XTBS supplemented with 0.1% Tween 20], followed by
primary antibody incubation overnight at 4 °C [anti-
APE1: 1:1.000 monoclonal (Novus); anti-Mia40: 1:500
polyclonal (costumed produced by APS Antibody Pro-
duction Services); anti-FLAG: 1:1.000 monoclonal
(Sigma); anti-ATP5A: 1:2.000 monoclonal (Abcam);
anti-LSD1: 10.000 polyclonal (Abcam); anti-Actin: 1:
2.000 polyclonal (Sigma Aldrich)]. Membranes were
washed three times for 5 min with TBS-T, incubated for
2 h with the secondary antibody, and washed again for
three time. The signal was detected with the Odyssey
CLx scanner (Li-Cor Bioscience) and densitometric ana-
lysis was performed with ImageStudio software (Li-Cor
Bioscience). In accordance with our Digital Image Integ-
rity Policy uncropped Western blot images have been in-
cluded as Supplementary Materials.
DNA extraction and mtDNA damage analysis in cell lines
DNA was extracted using Qiagen genomic-tip 20/G and
following manufacturer’s indications. After isolation
DNA was precipitated overnight with isopropanol, and
then 10 μg were digested with Formamidopyrimidine
DNA Glycosylase (Fpg) enzyme at 37 °C for 30 min to
remove damaged bases leaving an abasic (AP) site. Fpg
was inactivated at 60 °C for 10 min and DNA was precip-
itated overnight, resuspended in 50 μL of Tris-EDTA
buffer pH 8.0. Quantification was determined with
Quant-iT™ PicoGreen™ dsDNA Reagent (Invitrogen), ac-
cording to manufacturer’s instructions and DNA con-
centration was adjusted to 3 ng/μL.
mtDNA lesions were quantified by Q-PCR, using the
following primers: Mitolong Forward: 5′-TCT AAG
CCT CCT TAT TCG AGC CGA-3′ and Mitolong Re-
verse: 5′-TTT CAT CAT GCG GAG ATG TTG GAT
GG-3′ which amplified an 8.9 Kbp mitochondrial frag-
ment; Mitoshort Forward: 5-CCC CAC AAA CCC CAT
TAC TAA ACC CA-3′ and Mitoshort Reverse: 5′-TTT
CAT CAT GCG GAG ATG TTG GAT GG-3′ which
amplified a 221 bp mitochondrial fragment. DNA was
amplified using Platinum™ SuperFi™ DNA Polymerase
(Invitrogen) using the following protocol: 2 min at 94 °C,
18 cycles of denaturation for 15 s at 94 °C, annealing for
10 s at 66 °C, extension for 5.30 min at 68 °C for the 8.9
Kb fragment or annealing 45 s at 60 °C and extension for
45 s at 72 °C for the 221 bp fragment. A final extension
for 10 min at 68 or 72 °C was performed for each frag-
ment. To ensure quantitative conditions a sample with
the 50% of template amount was included in each ampli-
fication and, as negative control, a sample without the
template were used. PCR products were quantified in
triplicate by using Quant-iT™ PicoGreen™ dsDNA Re-
agent (Invitrogen). The Mitoshort fragment was used to
calculate the relative amount of mtDNA copies and to
normalize the lesions frequency calculated with the
Mitolong fragment [43].
Clonogenic assay
For the clonogenic assay, 500 cells were plated the day
before the beginning of the silencing. After 10 days, cells
were stained with 0.5% (wt/vol) methyl violet. Four bio-
logical replicates were preformed and for each replicate
four 10 cm2 plates per clone were analyzed. Plates were
imaged using a live scanner (GE Healthcare). The ana-
lysis was performed using a modified CellProfiler pipe-
line for colonies counting [44]. Briefly, the pipeline used
was based on four steps: background correction, identifi-
cation of the single plate, colony detection, and measure-
ment of colonies parameters. Colonies were identified
using the module Identify Primary Object with three
classes intensity threshold: foreground, middle and back-
ground. Middle class pixels were then categorized as
background, to avoid overestimation of the colony area.
Oxygen consumption rate (OCR)
OCR was determined by direct measurement with a Sea-
Horse Extracellular Flux Analyzer XpE instrument (Agi-
lent Technologies). OCR for the mitochondrial stress
test was determined following the manufacturer’s in-
structions. OCR of HeLa stable clones was measured at
baseline and after the addition of the stressors oligomy-
cin to evaluate ATP production, FCCP to measure the
maximal respiration and rotenone and antimycin A for
the spare capacity calculation. Time and type of stressor
administration are indicated in the graph (Fig. 3a). For
statistical analyses, all OCR values were normalized with
those of SCR.
Statistical analysis
Statistical analysis was performed using the Microsoft
Excel. One-way ANOVA was used for three group com-
parisons and Student’s t-test was used for two group
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comparisons. p values of less than 0.05 were considered
as significant, while values less than 0.01 or lower were
considered as highly significant.
Results
Mitochondrial accumulation of APE1 in grades 1 and 2
prevents mtDNA damage
IHC analysis was performed to determine the tumor grade
for each patient and to evaluate whether APE1 expression
and localization changed during the staging. As seen in
Fig. 1a, APE1 shows a weak/moderate cytoplasmic positiv-
ity in Grades 1 and 2 and a strong cytoplasmic expression
in Grade 3. Statistical analysis confirmed this trend, show-
ing a higher number of cytoplasmic positive hepatocytes
in Grade 3 compared with lower grades (Fig. 1b). Next, we
measured the relative levels of mtDNA damage of the
tumor tissue as compared to the non-tumor area of the
same patient. In Grades 1 and 2, mtDNA was less dam-
aged in the tumor compared to the distal tissue, while in
Grade 3 mtDNA the number of lesions was significantly
higher (Fig. 1c). Based on this data, we decided to verify
whether APE1’s cytoplasmic positivity observed in IHC
analysis accounted for the protein’s accumulation within
the mitochondrial compartment and therefore justified
the lower levels of mtDNA damage measured. Western
blot analyses of nuclear (NCE) and mitochondrial (MCE)
protein extracts from non-tumor (Distal) and HCC
(Tumor) confirmed that Grades 1 and 2 were character-
ized by a significantly higher amount of APE1 in mito-
chondria in the tumor compared to the distal area of all
patients, while Grade 3 showed the opposite pattern (Fig.
1d and Supplementary Figure 1). Altogether, these data
suggest that APE1’s cytoplasmic positivity in Grades 1 and
2 reflects an increased amount of mitochondrial APE1,
explaining the lower levels of mtDNA damage observed.
In contrast, the cytoplasmic positivity in Grade 3 is not as-
sociated with APE1’s mitochondrial accumulation, thus
accounting for the higher number of mtDNA lesions in
that grade.
In a previous study we identified the MIA pathway as
responsible for the mitochondrial translocation of APE1
[25]. To verify if mitochondrial accumulation of APE1
was somehow associated with an upregulation of its im-
port pathway, we analyzed the amount of Mia40, the
main player in this pathway (Fig. 1d). The trend was
similar to that of APE1, confirming the direct correlation
between Mia40 and APE1 expression and the enhanced
mitochondrial DNA damage repair capacity in lower
tumor grades.
Expression of APE1 only in mitochondria is sufficient to
sustain cell growth and cellular respiration
Having established a correlation between the tumor
stages, the amount of APE1 in mitochondria, and the
extension of mtDNA damage, we decided to fully inves-
tigate the role of APE1’s mitochondrial form in HCC
progression. Initially we tried to develop on hepatic cell
lines JHH6 and Huh7 a conditional knock-down of
APE1 by RNAi technology, as we already did in HeLa
cell line [40], to study molecular changes associated to
loss of APE1 functions. Unfortunately, we have not been
able to select any positive clones, and therefore we de-
cided to developed a stable cell line where APE1’s NLS
has been substituted by the MTS of MnSOD2 to drive
all ectopic protein into the mitochondrial matrix (MTS-
APE1). As a control we used a knock-in (KI) clone ex-
pressing wild-type APE1 (APE1 WT). The expression of
both ectopic proteins was performed on the background
of a stable inducible APE1 silencing clone already devel-
oped in our laboratory [40]. Scramble control (SCR) and
inducible shRNA (shRNA) clones were also included in
our analyses. The expression levels and localization of
ectopic 3X-FLAG tagged proteins were confirmed by
Western blot analyses (Fig. 2a and Supplementary Figure
2). Total (TCE), nuclear (NCE), and mitochondrial
(MCE) protein extracts were isolated as described in the
materials and methods section. Fifteen μg of total, 15 μg
of nuclei, and 40 μg of mitochondria protein extracts
were loaded on SDS-PAGE, transferred to nitrocellulose
membrane, and analyzed to evaluate the expression of
endogenous (α-APE1) and ectopic (α-FLAG) APE1.
Doxycycline treatment efficiently silenced endogenous
APE1. In APE1 WT clones, ectopic protein is present in
both the nuclear and mitochondrial compartments,
while in MTS-APE1 clones the mitochondrial targeting
sequence efficiently drives all ectopic protein into the
mitochondrial matrix (Fig. 2a). This cellular model
allowed us to discriminate between the mitochondrial
form of APE1 and its nuclear counterpart.
Nowadays, the only biological function described for
APE1 in mitochondria is its role in the base excision re-
pair (BER) pathway. To support the validity of our cellu-
lar model for studying the relevance of the
mitochondrial APE1 form in tumor cells, we measured
the levels of mtDNA damage. As previously reported,
loss of APE1 expression led to increased levels of
mtDNA damage, while the re-expression of APE1 WT
rescued the phenotype [25]. Remarkably, re-expression
of the MTS-APE1 also resulted in reducing the levels of
mtDNA damage, confirming the validity of the model
for studying the role of mitochondrial APE1 in cell
physiology (Fig. 2b).
To evaluate if the expression levels of APE1 in mito-
chondria may influence cell phenotype, we performed a
clonogenic assay (Fig. 2c). This assay is aimed to esti-
mate the ability of a single cell to form a colony and
consequently to evaluate its proliferation ability. The
same number of cells from each clone (500 cells/petri)
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was plated and grown for 10 days in the presence of
doxycycline. Then, colonies were stained with methyl
violet and the number of colonies and their area were
counted using CellProfiler (Fig. 2c). As we already re-
ported in another manuscript [40], and similar to the
previously reported evidence using different cell lines
[45], clonogenic assay showed a strong inhibition of cell
growth in the silenced clone. The growth inhibition was
efficiently rescued by the expression of APE1 WT [41].
Interestingly, we also observed a complete rescue of the
phenotype in the MTS-APE1 clone, suggesting a funda-
mental role of the mitochondrial form of APE1 in cell
growth processes (Fig. 2d, left panel). Next, we analyzed
the dimension of the colonies, observing that when
APE1 is driven into mitochondria, colonies are signifi-
cantly bigger compared to both silenced (shRNA) or
APE1 overexpressing cells (APE1 WT) (Fig. 2d, right
panel), suggesting that APE1 expression levels in mito-
chondria may impact cell growth during the early phases
of tumor progression.
Because the localization of APE1 in mitochondria
allowed the protein to modify the colonies’ phenotype,
thus improving their proliferation, we decided to further
investigate if mitochondria physiology was affected by
mitochondrial expression levels of APE1. For this pur-
pose, the Oxygen Consumption Rate (OCR) of APE1
shRNA and KI clones was measured using Seahorse
extracellular flux analyser (Fig. 3a). Loss of APE1 expres-
sion determined significant reduction of both the basal
and maximum respiration levels, as well as ATP produc-
tion (Fig. 3b). All parameters were efficiently rescued in
APE1 WT clones. The MTS-APE1 cells’ ability to re-
establish SCR levels of OCR and ATP production was
impressive (Fig. 3b). Our data show that the presence of
APE1 within the mitochondrial matrix is enough to im-
prove all the considered parameters.
Discussion
The APE1 protein’s importance in maintaining cell
homeostasis by playing a major role in the BER pathway
and thereby preserving the integrity of nuclear DNA has
been broadly discussed [41, 42, 45–50]. Because of its
crucial role, APE1 has been described as one of the fac-
tors involved in the development of numerous cancer
types, and its overexpression has been associated with
poor prognosis for patients [51–54]. However, until re-
cently, researchers mainly focused on the nuclear frac-
tion of APE1, despite the knowledge that it also may
localize in the mitochondrial compartment [20, 21]. In-
deed, cytoplasmic re-localization of APE1 has been
found to be associated with a higher tumor aggressive-
ness and a poorer prognosis for patients with HCC [38].
In a previous work, we demonstrated that the MIA path-
way is involved in the translocation of APE1 into the
mitochondrial compartment, contributing to the main-
tenance of mitochondrial genome stability [25]. By using
siRNA technology on HeLa cells and JHH6 hepatic cell
line we proved that loss of Mia40 expression determined
an increase of mtDNA damage under oxidative stress
conditions. Moreover, analysing the expression levels of
Mia40 and APE1 in hepatic cell lines JHH6 and Huh7
we demonstrated the role of the MIA pathway in the
translocation of APE1 and that loss of Mia40 expression
negatively affects the mitochondrial levels of APE1 pro-
tein [25]. Moreover, a recent manuscript by Li et al.
shows how overexpression of APE1 and Mia40 enhances
cisplatin resistance and autophagy of A549 cells [55].
In the present study, we further investigated the sig-
nificance of mitochondrial APE1, particularly in the con-
text of HCC development. As an in vivo model we
analysed a cohort of patients affected by HCC who
underwent surgical resection. Diagnosis and tumor grade
were confirmed by IHC analyses. We also evaluated
APE1 expression and localization, revealing that the in-
creased cytoplasmic positivity observed in Grades 1 and
2 accounted for the higher amount of mitochondrial
APE1 and the lower levels of mtDNA damage in the
tumor tissue with respect to the distal area measured. In
accordance with our model and the data reported in lit-
erature, the expression levels of Mia40 were also found
to be upregulated, justifying the higher amount of APE1
observed in the mitochondrial compartment. In contrast,
compared with lower-grade patients, Grade 3 patients
showed higher numbers of cytoplasmic positive hepato-
cytes, reduced expression levels of APE1 and Mia40, and
a significantly higher number of DNA lesions. In the co-
hort of patients analyzed there have been eight recur-
rences, one of which was previously classified as Grade 3
and seven as Grade 2. In six of those Grade 2 patients
the levels of mtDNA damage were lower in the tumor
(See figure on previous page.)
Fig. 1 HIC, Western blot analysis and mtDNA damage quantification in human HCC samples. a Representative images of non-tumor, Grades 1, 2
and 3 samples stained with hematoxylin/eosin (20x) (upper panel) and APE1 (20x) (lower panel). b Graph showing the percentage of APE1’s
cytoplasmic positive cells in tumor tissues. c Graph showing the relative levels of mtDNA damage of tumor tissue with respect to the distal non-
tumor area of the same patient. d Representative Western blot analyses of nuclear and mitochondrial protein extracts of Grades 1–2 and Grade 3
tumor samples (upper panel). The graphs (lower panel) show the relative amounts of Mia40 and APE1 in the tumor tissues (Tumor) with respect to
the distal non-tumor area (Distal) of the same patient. Anti-LSD1 antibodies and anti-ATP5A proteins were used as nuclear and mitochondrial
markers, respectively. Full-length blots are presented in Supplementary Figure 1. (*: p < 0.05)
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Fig. 2 (See legend on next page.)
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Fig. 2 Characterization of APE1 WT and mitochondrial targeted (MTS-APE1) clones. a Western blot analysis of total (TCE), nuclear (NCE), and
mitochondrial (MCE) protein extracts of control (SCR), APE1 shRNA (shRNA), APE1 WT, and MTS-APE1 HeLa clones. Endogenous APE1 is efficiently
silenced by a shRNA clone, while ectopic 3xFLAG-tagged APE1 is present only in APE1 WT and MTS-APE1 clones. While in the APE1 WT clone the
ectopic protein localizes into both the nuclear and mitochondrial compartments, in MTS-APE1 clones the signal is mostly present in the MCE.
Moreover, ectopic MTS-APE1 pre-protein (*) is processed into the mitochondrial matrix where the MTS is removed (**), leaving the active APE1
form. Anti-LSD1 antibodies and anti-ATP5A proteins were used as nuclear and mitochondrial markers, respectively, while anti-Actin as loading
control. Full-length blots are presented in Supplementary Figure 2. b mtDNA damage was quantified in each clone. The silencing of APE1 causes
a significant increase in the damage detected, while the re-expression of the ectopic APE1 WT or MTS-APE1 restores the basal mtDNA damage.
The error bar represents the standard deviation of three independent experiments. (*: p < 0.05). c Representative images of clonogenic assay on
APE1 shRNA and stable KI clones. In the zoomed squares it is possible to appreciate the size difference between APE1 WT and MTS-APE1
colonies. d The graphs report the relative number of colonies (left panel) and the colonies’ dimension (right panel) of shRNA, APE1 WT, and MTS-
APE1 clones compared to the control clone (SCR). Data reported are the mean of four independent biological replicates. (*: p < 0.05; **: p < 0.01;
***: p < 0.001)
Fig. 3 Effect of APE1 silencing on mitochondrial respiratory parameters. a Profiles of mitochondria bioenergetics measurements measured with
Seahorse. Time and type of stressor administration are indicated. b The graph displays the relative average (±SD) basal and maximal respiration,
as well as ATP production of HeLa clones silenced for APE1 expression (shRNA) and after re-expression of APE1 in all cells (APE1 WT) or only into
the mitochondrial matrix (MTS-APE1). Data reported are the mean of four independent biological replicates. (*: p < 0.05; **: p < 0.01)
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tissue respect to the distal area and the percentage of
APE1 cytoplasmic positive cells was between 40 and
60%. This observation further support the role of mito-
chondrial APE1 in tumor development and cellular mi-
gration processes.
To better understand the role of APE1 mitochon-
drial fraction, we generated a stable cell line where
APE1’s NLS has been substituted by the MTS of
MnSOD2 to drive all ectopic protein into the mito-
chondrial matrix (MTS-APE1). Remarkably, the pres-
ence of APE1 within the mitochondrial matrix was
sufficient to rescue respiration, cell viability, and
proliferation as well as mtDNA levels, all of which
were negatively affected by APE1’s loss of
expression.
Our data suggest that during the early phase of tumor
development (Grades 1 and 2), while cell proliferation is
at its highest [56, 57] and the accumulation of mutations
is relatively low [57], the high-energy demand to sustain
an enhanced cell metabolism requires increased ATP
production via oxidative phosphorylation generating
more ROS. Therefore, maintaining mitochondrial stabil-
ity is crucial, and this justifies the increased amount of
APE1 present in this organelle in Grades 1 and 2 pa-
tients. In these stages, overexpression of Mia40 increases
the import of APE1, contributing to the maintenance of
mtDNA integrity. In contrast, during the latest tumor
stage (Grade 3), when the overall cell fitness is impaired
by accumulation of the mutations, the efficiency of the
protein transport into the mitochondria can be signifi-
cantly decreased. This explains why the cytoplasmic
positivity in Grade 3 is not associated with APE1’s
mitochondrial accumulation, and accounts for the higher
number of mtDNA lesions measured in the tumor tissue
with respect to the distal area (Fig. 4). In accordance
with our data, in a recent manuscript Pascut et al. de-
tected the presence of APE1 in the serum of HCC pa-
tients, suggesting this parameter as a possible biomarker
for tracking cancer progression [58].
Conclusions
Results obtained by analysing the patients’ cohort are
in agreement and extend with an in vivo model the
previously published data correlating tumor develop-
ment with APE1 expression and localization. To our
knowledge, this is the first study on patients’ samples
where mitochondrial APE1 expression has been evalu-
ated and correlated with the levels of mtDNA damage
and the tumor stage. Our data clearly indicate a lead-
ing role of the mitochondrial form of APE1 in the
early stages of cancer development and the relevance
of the non-nuclear fraction of APE1 in the disease
progression. In our model, the mitochondrial form of
APE1 is essential in protecting the mtDNA and in
this way preserving the cells’ ability to actively prolif-
erate (Fig. 4). Our study has also confirmed overex-
pression of Mia40 and the role of the MIA pathway
in the APE1 import process. Overall, our findings
clearly illustrate that inhibition of the APE1 transport
by blocking the MIA pathway could become an alter-
native therapeutic approach. This procedure would
trigger reduction of the mitochondrial metabolism,
which would prevent efficient repair of mtDNA.
Fig. 4 Role of mitochondrial APE1 in HCC tumor progression. In healthy cells, APE1 localization is mainly nuclear. Nevertheless, a physiological
amount of the protein is also present in mitochondria (healthy cell). During tumorigenic processes and in low grade tumors, APE1 is
overexpressed. Increased expression of its mitochondrial transporter Mia40 determines increased levels of mitochondrial APE1, which determines
a higher rate of mtDNA repaired. In high grade tumors, APE1 delocalizes from nuclei to cytoplasm; mitochondria show dysfunction, the protein
import is impaired, and less APE1 is detected in the organelle. At this final stage, exosomes containing APE1 have been detected in
serum (sAPE1)
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